US-based vTv Therapeutics granted China-based Newsoara Biopharma Co., Ltd an exclusive worldwide license to develop and commercialize its orally administered PDE4 inhibitor HPP737, a small-molecule anti-inflammatory candidate, under an amended agreement that broadens an earlier regional license and includes a sizeable upfront payment and milestone structure. The deal positions Newsoara to pursue global development and potential commercialization in inflammation-mediated disease areas, extending beyond the China-centric rights previously held under the original licensing arrangement. The companies said the amendment could materially support vTv’s balance sheet while advancing HPP737’s clinical trajectory and global reach.

Under the amended terms, Newsoara delivered an upfront payment of USD 20 million to vTv and secured the right to a global license to develop and commercialize HPP737 across all territories. In addition to the upfront fee, the agreement provides for development milestones of up to USD 50 million and sales milestones of up to USD 65 million, with tiered royalties on net sales. The licensing expansion transforms the original 2018 deal, which granted Newsoara rights in China and certain Pacific Rim territories.

Deal context: PDE4 inhibitors

HPP737 is a selective phosphodiesterase type 4 (PDE4) inhibitor, a mechanism that raises intracellular cyclic adenosine monophosphate (cAMP) to exert broad anti-inflammatory effects. PDE4 inhibitors are a validated class for indications such as psoriasis and atopic dermatitis, though their utility has historically been constrained by dose-limiting gastrointestinal adverse effects with marketed agents. Preclinical and early clinical data disclosed by both companies indicate that HPP737 demonstrated potent inhibition of interleukin-23 and tumor necrosis factor-α in vitro and in vivo and was generally well-tolerated in Phase I studies, with limited gastrointestinal distress — a profile Newsoara characterized as potentially differentiating within the class.

The asset has been advanced into Phase II trials in indications including psoriasis and chronic obstructive pulmonary disease in China under Newsoara’s stewardship, and a Phase III psoriasis program.

PDE4 inhibition is a well-established anti-inflammatory strategy with approved drugs such as apremilast (Amgen’s Otezla) for psoriasis and roflumilast for chronic obstructive pulmonary disease; HPP737’s development aims to combine oral convenience with an improved tolerability profile.